Clinical Trials Logo

Advanced Neoplastic Disease clinical trials

View clinical trials related to Advanced Neoplastic Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01907685 Completed - Clinical trials for Advanced Neoplastic Disease

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Start date: June 2006
Phase: Phase 1
Study type: Interventional

Primary Objective: To determine the dose limiting toxicity (DLT), the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of AVE8062 and docetaxel in combination administered sequentially on D1 & D2 respectively every 3 weeks in patients with advanced solid tumors. Secondary Objectives: - To define the overall safety profile of the combination. - To characterize the pharmacokinetic (PK) profile of AVE8062 and docetaxel when administered in combination. - To evaluate anti-tumor activity of the combination. - To evaluate potential predictive biomarkers. The study includes a tumoral pharmacogenomic sub-study conducted in a subset of sites. The objective to analyse a set of biological biomarkers in order to identify a potential predictive signature of efficacy for AVE8062 in combination with docetaxel.